Treatment of fibrosis with interleukin-11 antibody
Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
1. A method of treating a disease or condition characterised by fibrosis of an organ of the gastrointestinal system in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 (IL-11) antibody which is capable of inhibiting IL-11 mediated signaling.
2. The method according to claim 1 , wherein the disease or condition is characterised by fibrosis of the intestine, small intestine, large intestine, liver, or pancreas.
3. The method according to claim 1 , wherein the disease or condition is selected from the group consisting of Crohn's disease, microscopic colitis, and primary sclerosing cholangitis (PSC).
4. The method according to claim 1 , wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.
5. The method according to claim 1 , wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.
6. The method according to claim 1 , wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression has been determined to be upregulated.
7. The method according to claim 1 , wherein the method comprises determining whether IL-11 or IL-11R expression is upregulated in the subject and administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.
8. The method of claim 2 , wherein the intestine is the small intestine or the large intestine.
9. A method of treating a disease or condition characterised by fibrosis selected from the group consisting of Crohn's disease, microscopic colitis, and primary sclerosing cholangitis (PSC) in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 (IL-11) antibody which is capable of inhibiting IL-11 mediated signaling.
10. The method according to any claim 9 , wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.
11. The method according to any claim 9 , wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.
12. The method according to any claim 9 , wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression has been determined to be upregulated.
13. The method according to any claim 9 , wherein the method comprises determining whether IL-11 or IL-11R expression is upregulated in the subject and administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.